Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BioNTech SE

0A3M
Current price
112.3 USD 0 USD (0.00%)
Last closed 106.64 USD
ISIN US09075V1026
Sector Healthcare
Industry Biotechnology
Exchange London IL
Capitalization 26 506 153 984 USD
Yield for 12 month +11.40 %
1Y
3Y
5Y
10Y
15Y
0A3M
21.11.2021 - 28.11.2021

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac Address: An der Goldgrube 12, Mainz, Germany, 55131

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

131.28 USD

P/E ratio

Dividend Yield

Current Year

+4 153 538 447 USD

Last Year

+18 826 981 577 USD

Current Quarter

+139 973 919 USD

Last Quarter

+140 681 888 USD

Current Year

+3 501 196 902 USD

Last Year

+13 897 985 441 USD

Current Quarter

+74 935 533 USD

Last Quarter

+75 314 547 USD

Key Figures 0A3M

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -621 500 032 USD
Operating Margin TTM -747.32 %
PE Ratio
Return On Assets TTM -2.21 %
PEG Ratio 0.0449
Return On Equity TTM -2.59 %
Wall Street Target Price 131.28 USD
Revenue TTM 2 690 599 936 USD
Book Value 80.22 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -23.3 %
Dividend Yield
Gross Profit TTM 16 065 200 000 USD
Earnings per share -2.31 USD
Diluted Eps TTM -2.31 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY -79.5 %
Profit Margin -18.75 %

Dividend Analytics 0A3M

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

5 %

Dividend History 0A3M

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 02.06.2022
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 17.06.2022

Stock Valuation 0A3M

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 7.0373
Enterprise Value Revenue 2.7177
Price Sales TTM 9.8514
Enterprise Value EBITDA 110.8146
Price Book MRQ 1.2799

Financials 0A3M

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 0A3M

For 52 weeks

76.53 USD 131.49 USD
50 Day MA 109.72 USD
Shares Short Prior Month 1 859 038
200 Day MA 95.02 USD
Short Ratio 2.15
Shares Short 2 412 606
Short Percent 5.03 %